Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

Study acronym: LUTHREE
StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Primary and study completion dates: May 2021 to Jan 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Eligibility criteria expanded, about 181 words
    • Site details revised
    v3
  3. Eligibility criteria expanded, about 33 wordsv2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate
Trial Details
NCT Number NCT03454763
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions
(from sponsor)		 Neuroendocrine Tumors
Related terms Neuroendocrine Tumors
Enrollment 618 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov